BioNTech (BNTX) Stock Forecast & Price Target

$89.94

-0.21 (-0.23%)

(As of 09/6/2024 ET)

BioNTech - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy
Based on 12 Analyst Ratings

Based on 12 Wall Street analysts who have issued ratings for BioNTech in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 1 has given a sell rating, 5 have given a hold rating, 5 have given a buy rating, and 1 has given a strong buy rating for BNTX.

Consensus Price Target

$109.09
21.29% Upside

High Forecast	$171.00
Average Forecast	$109.09
Low Forecast	$85.00

According to the 12 analysts' twelve-month price targets for BioNTech, the average price target is $109.09. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $85.00. The average price target represents a forecasted upside of 21.29% from the current price of $89.94.

Type	Current Forecast 9/8/23 to 9/7/24	1 Month Ago 8/9/23 to 8/8/24	3 Months Ago 6/10/23 to 6/9/24	1 Year Ago 9/8/22 to 9/8/23
Consensus Rating	Moderate Buy	Moderate Buy	Hold	Moderate Buy
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	5 Buy rating(s)	5 Buy rating(s)	3 Buy rating(s)	5 Buy rating(s)
Hold	5 Hold rating(s)	5 Hold rating(s)	6 Hold rating(s)	5 Hold rating(s)
Sell	1 Sell rating(s)	1 Sell rating(s)	1 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$109.09	$109.00	$111.70	$158.69
Forecasted Upside	21.29% Upside	20.91% Upside	18.88% Upside	34.76% Upside

Get BioNTech Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for BNTX and its competitors with MarketBeat's FREE daily newsletter.

Ad Porter & Company

Trump’s weapon lurks in abandoned America

Unemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…

Go here now to watch my new documentary

BNTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BNTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

BioNTech Stock vs. The Competition

Type	BioNTech	Medical Companies	S&P 500
Consensus Rating Score	2.50	2.77	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	21.29% Upside	1,206.55% Upside	11.36% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/27/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$113.00 ➝ $113.00	+29.13%
8/15/2024	JPMorgan Chase & Co. 3 of 5 stars		Lower Target	Underweight ➝ Underweight	$94.00 ➝ $91.00	+7.25%
8/7/2024	Deutsche Bank Aktiengesellschaft 2 of 5 stars		Upgrade	Hold ➝ Buy	$95.00 ➝ $95.00	+19.50%
8/6/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$98.00 ➝ $85.00	+7.50%
8/2/2024	Hsbc Global Res Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Kumar Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
8/2/2024	HSBC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy
Get the Latest News and Ratings for BNTX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.
5/14/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	C. Kasimov Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Inline	$100.00	+7.85%
5/7/2024	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$123.00 ➝ $122.00	+32.90%
3/27/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$110.00 ➝ $101.00	+8.73%
3/21/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy ➝ Buy	$171.00	+87.66%
2/28/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$113.00 ➝ $100.00	+8.80%
1/5/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
11/8/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $111.00	+11.70%
5/17/2023	Redburn Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Buy	$165.00 ➝ $170.00	+60.98%
3/28/2023	Berenberg Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Zhiqiang Shu Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$260.00	+111.38%
3/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Akash Tewari Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Target		$145.00	+17.31%
3/27/2023	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$239.00 ➝ $194.00	+56.96%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 10:09 PM ET.

BNTX Forecast - Frequently Asked Questions

What is BioNTech's forecast for 2024?: According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for BioNTech is $109.09, with a high forecast of $171.00 and a low forecast of $85.00.
Should I buy or sell BioNTech stock right now?: 12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last year. There is currently 1 sell rating, 5 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BNTX shares.
Does BioNTech's stock price have much upside?: According to analysts, BioNTech's stock has a predicted upside of 21.73% based on their 12-month stock forecasts.
Has BioNTech been upgraded by Wall Street analysts recently?: Over the previous 90 days, BioNTech's stock had 3 upgrades by analysts.
What analysts cover BioNTech?: BioNTech has been rated by research analysts at Deutsche Bank Aktiengesellschaft, HC Wainwright, Hsbc Global Res, HSBC, JPMorgan Chase & Co., and TD Cowen in the past 90 days.
Do Wall Street analysts like BioNTech more than its competitors?: Analysts like BioNTech less than other "medical" companies. The consensus rating score for BioNTech is 2.50 while the average consensus rating score for "medical" companies is 2.77. Learn more on how BNTX compares to other companies.